Teen's death at center of new lawsuit | Surgery outperforms GLP-1 drugs | Long-term antidepressant use & SCD

The family of a teenage girl who died unexpectedly in 2025 has sued two energy drink distributors.

Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.

The FDA asked, and Eli Lilly and Company delivered. The company now hopes to secure an additional approval for orforglipron/Foundayo that covers the treatment of type 2 diabetes.

The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.

Nearly 27,000 MiniMed 780G insulin pumps were included in a new Class II recall. By taking a few basic steps, however, patients should be able to avoid any significant risks.

Starting menopause before the age of 40 could increase a woman's lifetime risk of coronary heart disease by up to 40%.

Targeting key cardiovascular risk factors for two full years was not linked to a reduced risk of cognitive decline or dementia.